Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX)
· seekingalpha.com
Edgewise has transformed into a well-capitalized cardiovascular drug developer following the sale of sevasemten to Servier. Read more on EWTX stock here.
I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and in...